Ocular Neurology
Tern Therapeutics LLC is focused on the treatment of ocular manifestations associated with Neuronal Ceroid Lipofuscinosis type 2, with attention to the eye-related complications of this rare inherited disorder.
- CLN2 disease
- Ocular manifestations
- Inherited lysosomal storage disorders
The sponsor’s current clinical research activity is centered on a single ongoing study in this rare pediatric neurodegenerative disease area, reflecting a therapeutic interest in vision-related disease burden.
Rare Disease Therapeutics
The company’s clinical portfolio includes research in rare disease medicine, specifically within a genetic neurological disorder that affects both the nervous system and the eyes.
- Genetic neurodegeneration
- Rare inherited disorders
- Neurologic and ophthalmic overlap
This area of interest places emphasis on conditions with limited treatment options and specialized clinical needs.
Ophthalmic Disease
Research activity is directed toward eye involvement in CLN2 disease, highlighting therapeutic interest in retinal and broader visual pathway complications linked to systemic disease.
- Visual impairment
- Retinal involvement
- Eye disease in neurogenetic conditions
Clinical interest in this domain supports investigation of treatments aimed at preserving or stabilizing ocular function in affected participants.
